Ingenol disoxate

Drug Profile

Ingenol disoxate

Alternative Names: LEO-43204

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Class Antiacnes; Antineoplastics; Carboxylic acids; Cyclopropanes; Esters; Isoxazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis; Squamous cell cancer
  • Phase II Acne vulgaris

Most Recent Events

  • 10 Aug 2017 LEO Pharma completes a phase III trial in Actinic keratosis in USA and Germany (NCT02549339)
  • 01 Aug 2017 LEO Pharma completes a phase III trial in Actinic keratosis in USA and United Kingdom (Topical) (NCT02547363) (EudraCT2015-002451-10)
  • 01 Aug 2017 LEO Pharma completes a phase III trial in Actinic keratosis in Germany (NCT02549352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top